BRAF and colorectal carcinoma: Recent studies in CRC from our group showed that rafoxanide (1.25–5 μM) restrained the growth of human CRC cells—bearing both the mutated V600E (HT-29) and wild-type BRAF alleles (HCT-116 and DLD-1)—but not that of normal colonic epithelial cells [41].